The FDA accepted a new drug application for a single inhaler that contains beclomethasone dipropionate, formoterol fumarate ...
The FDA has accepted for review the NDA for Chiesi’s single inhaler triple therapy for the maintenance treatment of asthma in adults.
Asthma remains a significant health burden in the U.S., with more than 60% of adults continuing to experience frequent symptoms despite the ...
Inhalers for asthma and COPD generate substantial greenhouse gas emissions; UCLS researchers quantify carbon footprint in the ...
A new study has found that some asthma treatments carry a bigger carbon footprint. Associate Professor Tan Ngiap Chuan, director of research at SingHealth Polyclinics and the study's author, shared ...
Inhalers are life-saving tools for millions of people living with asthma and chronic obstructive pulmonary disease (COPD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback